Opendata, web and dolomites

OSTEOproSPINE SIGNED

Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OSTEOproSPINE project word cloud

Explore the words cloud of the OSTEOproSPINE project. It provides you a very rough idea of what is the project "OSTEOproSPINE" about.

crest    evaluation    blinded    disorders    restore    human    allograft    resistant    morphogenetic    centers    randomized    intractable    approval    efficacy    suffering    form    regenerative    13    grant    signals    harvested    distal    vienna    assembled    compression    designed    enroll    recombinant    excellent    clinical    guide    surgery    osteogrow    profile    permissive    evaluator    spinal    conditional    molecular    patients    fp7    posterolateral    rate    279239    coagulum    humans    weight    iliac    regeneration    radius    quality    degenerative    replace    spine    back    functioning    life    trial    supporting    site    treatment    medicine    fusion    ethics    fracture    cells    therapy    180    disc    granted    extra    matrix    reduce    administration    outcome    safety    patient    microenvironment    delivered    lumbar    presumptive    positive    peripheral    severity    pain    reinforced    tibial    bone    exhibited    chronic    standard    function    rhbmp6    vertebrae    bearing    blood    autograft    committee    ground    disease    population    autologous    osteotomy    correct    trials    osteoprospine    care    confirm    skeletal    generating    health    conduct    protein   

Project "OSTEOproSPINE" data sheet

The following table provides information about the project.

Coordinator
SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET 

Organization address
address: SALATA 3
city: ZAGREB
postcode: 10 000
website: www.mef.unizg.hr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Croatia [HR]
 Total cost 6˙004˙152 €
 EC max contribution 6˙004˙152 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET HR (ZAGREB) coordinator 710˙750.00
2    GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA HR (KALINOVICA) participant 1˙138˙750.00
3    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 848˙625.00
4    CLINRES FARMACIJA RAZISKAVE DOO SI (LJUBLJANA) participant 705˙762.00
5    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 454˙375.00
6    UNIVERSITAT LINZ AT (LINZ) participant 423˙750.00
7    2KMM SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA PL (KATOWICE) participant 377˙250.00
8    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 347˙500.00
9    QBEX GMBH AT (KLAGENFURT) participant 295˙346.00
10    SMART-MEDICO DOO HR (ZAGREB) participant 253˙532.00
11    UNIVERSITY OF ZAGREB-FACULTY OF VETERINARY MEDICINE HR (ZAGREB) participant 251˙250.00
12    TRIADELTA PARTNERI DOO ZA ISTRAZIVANJE I RAZVOJ HR (ZAGREB GRAD ZAGREB) participant 183˙107.00
13    PAUL REGULATORY SERVICES LIMITED UK (CARDIFF) participant 14˙154.00
14    OPCA BOLNICA VARAZDIN HR (VARAZDIN) participant 0.00

Map

 Project objective

We propose a clinical program for the evaluation of a novel bone-regeneration product OSTEOproSPINE as a treatment for intractable chronic back pain. OSTEOproSPINE is a novel bone regeneration therapy composed of OSTEOGROW (recombinant human bone morphogenetic protein 6 [rhBMP6] delivered in autologous peripheral blood coagulum) reinforced with allograft (a compression resistant matrix). OSTEOproSPINE is designed to guide the formation of new bone at extra-skeletal site and replace autograft harvested from patient’s iliac crest for the fusion of lumbar vertebrae. By generating new bone, OSTEOproSPINE will restore the spine’s weight bearing function, reduce the severity of back pain and improve the success rate of posterolateral spinal fusion surgery. The program consortium of 13 partners from 6 EU member states has been assembled to conduct a Phase II, randomized, patient- and evaluator-blinded clinical trial of OSTEOproSPINE. Four clinical centers will enroll 180 patients suffering from degenerative disc disease to assess OSTEOproSPINE efficacy and safety in comparison with Standard of care (autograft) and Osteogrow. The Ethics Committee of the leading clinical site in Vienna has already granted a conditional approval for this trial. As the coordinating institution of the FP7 HEALTH project Osteogrow (Grant No. 279239), we have evaluated Osteogrow in Phase I/II clinical trials for distal radius fracture and high tibial osteotomy. Osteogrow exhibited excellent safety profile in these trials, supporting OSTEOproSPINE safety for administration in humans. A positive outcome of proposed trial will confirm OSTEOproSPINE potential to form a functioning new bone in human and by this restore the spine’s function and improve the quality of life in patients with degenerative disc disorders using the ground principle of regenerative medicine: “provide the correct molecular signals to a population of presumptive cells in a permissive microenvironment”.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-10-03 18:11:11
Public project website Websites, patent fillings, videos etc. 2019-10-03 18:11:11

Take a look to the deliverables list in detail:  detailed list of OSTEOproSPINE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OSTEOPROSPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OSTEOPROSPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More